ripekg:author/RIPEAU3EF3EB3520520BD6Yanmei Xu |
rdf:type |
node1 |
ripekg:author/RIPEAU3EF3EB3520520BD6Yanmei Xu |
rdf:type |
rdfs:Resource |
ripekg:author/RIPEAU3EF3EB3520520BD6Yanmei Xu |
rdf:type |
owl:Thing |
ripekg:author/RIPEAU3EF3EB3520520BD6Yanmei Xu |
rdf:type |
prov:Person |
ripekg:author/RIPEAU3EF3EB3520520BD6Yanmei Xu |
rdf:type |
foaf:Person |
ripekg:author/RIPEAU3EF3EB3520520BD6Yanmei Xu |
rdf:type |
ripe:AuthorAuthor |
ripekg:author/RIPEAU3EF3EB3520520BD6Yanmei Xu |
owl:sameAs |
https://semopenalex.org/author/A5052785634 |
ripekg:author/RIPEAU3EF3EB3520520BD6Yanmei Xu |
foaf:familyName |
Xu |
ripekg:author/RIPEAU3EF3EB3520520BD6Yanmei Xu |
foaf:givenName |
Yanmei |
ripekg:author/RIPEAU3EF3EB3520520BD6Yanmei Xu |
foaf:name |
Yanmei Xu |
ripekg:retraction-notice/10205Study on corporate vitality from perspective of dynamic capabilities view |
ripe:concerns |
ripekg:author/RIPEAU3EF3EB3520520BD6Yanmei Xu |
ripekg:work/10.1136%2Fbmj-2025-084314Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial |
dcterms:creator |
ripekg:author/RIPEAU3EF3EB3520520BD6Yanmei Xu |